None listed
Conditions
Brief summary
Budesonide is an inhaled corticosteroid which is commonly used to treat asthma. It is inexpensive and widely available. Budesonide is a category A drug in pregnancy. There is evidence that budesonide reduces hospital admission in patients with covid-19 who are not pregnant. The physiological changes that take place in pregnancy include increased minute ventilation and upwards displacement of the diaphragm which results in a high-risk state for any kind of respiratory compromise. As such, treatments that reduce the risk of these fit young mothers suffering respiratory decompensation are pertinent to the well-being of both the baby and the mother. This study seeks to determine if budesonide improves outcomes in those hospitalised with covid-19.
Interventions
Budesonide inhaled 400micrograms 2 puffs twice per day while in hospital for up to 2 weeks.
This will be supervised by a nurse who will give the inhaler
Sponsors
Monash Health
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
covid symptoms requiring admission to hospital >==16 weeks gestation up to 6 weeks post partum ( including breastfeeding). Age >18 years Not requiring O2 Patients with comorbidities including but not limited to asthma ( not on budesonide), diabetes mellitis, hypertension and all others in which budesonide is not contraindicated
Exclusion criteria
O2 requiring on dexamethasone, remdesivir or tocilizumab Contraindication to budesonide or taking budesonide outside of trial
Outcome results
None listed